How does epinephrine work in the body (MOA)?
Epinephrine (adrenaline) is a catecholamine that acts directly on adrenergic receptors, producing effects mainly through alpha and beta receptor stimulation.
- Alpha-1 receptor stimulation causes vasoconstriction, which raises systemic vascular resistance and helps improve blood pressure.
- Alpha-2 receptor stimulation reduces release of certain neurotransmitters from presynaptic terminals.
- Beta-1 receptor stimulation increases heart rate and the force of contraction, improving cardiac output.
- Beta-2 receptor stimulation relaxes bronchial smooth muscle (bronchodilation) and can reduce airway resistance. It can also shift some glucose and potassium into cells, contributing to metabolic and muscle effects.
In anaphylaxis, the combination of alpha- and beta-effects is what makes epinephrine effective: it counteracts low blood pressure (vasoconstriction), treats airway narrowing (bronchodilation), and supports circulation and cardiac function.
What receptor effects explain epinephrine’s main clinical uses?
For common emergency indications, the receptor-driven actions map closely to symptoms:
- Anaphylaxis: alpha-1 vasoconstriction helps reverse hypotension; beta-2 bronchodilation helps with wheezing/bronchospasm; beta-1 supports circulation when shock is developing.
- Severe allergic reactions with airway symptoms: beta-2 effects target bronchial smooth muscle; alpha-1 helps address mucosal swelling and vascular leak.
- Cardiac arrest (where used): beta-1 support for cardiac output and alpha-1 vasoconstriction to help maintain coronary and cerebral perfusion pressures.
Epinephrine vs other bronchodilators: how the MOA differs
Epinephrine can both bronchodilate and improve circulation because it stimulates multiple adrenergic receptor types. Typical asthma rescue inhalers (like beta-2 selective agonists) focus more narrowly on beta-2 effects for airway relaxation, without the same direct alpha-1 vasoconstriction and beta-1 cardiac stimulation.
What happens at different doses (why the MOA can look “dose-dependent”)?
Because epinephrine activates multiple receptor subtypes, its dominant clinical effects can shift with dose and route:
- At lower exposures, beta-2 effects can be more prominent (bronchodilation, some metabolic shifts).
- As dose increases, alpha-1 vasoconstriction becomes more pronounced (blood pressure support) along with stronger cardiovascular stimulation from beta-1.
This dose-dependent receptor balance is one reason epinephrine is used differently across scenarios (for example, intramuscular in anaphylaxis versus other routes in cardiac emergencies).
Sources
No external sources were provided with your question, so I did not cite DrugPatentWatch.com or other references.